Fintel reports that on November 4, 2024, Leerink Partners initiated coverage of Zura Bio (NasdaqCM:ZURA) with a Outperform ...

In a report released on November 1, Jonathan Chang from Leerink Partners reiterated a Buy rating on Molecular Partners (MOLN – Research ...

Leerink Partners CIO Jeff Gerson on how the firm realigned its technology strategies and services after it demerged from SVB ...

Leerink Partners CIO Jeff Gerson on how the firm realigned its technology strategies and services after it demerged from SVB ...

BOSTON, Nov. 1, 2024 /PRNewswire/ -- Leerink Partners, a leading investment bank specializing in healthcare, is pleased to announce that Tom Davidson has joined as Co-President of the firm and Co ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.21% of ...

On Monday, Envista Holdings Corp (NVST) stock saw a modest uptick, ending the day at $21.28 which represents a slight increase of $0.34 or 1.62% from the prior close of $20.94. The stock opened at $21 ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Voyager Therapeutics (VYGR – Research Report), Align Tech ...

Fintel reports that on October 24, 2024, Leerink Partners initiated coverage of Tenax Therapeutics (NasdaqCM:TENX) with a ...

Fintel reports that on October 31, 2024, Leerink Partners upgraded their outlook for Envista Holdings (NYSE:NVST) from Underperform to Market Perform. As of October 22, 2024, the average one-year ...

On Friday, Leerink Partners maintained an Outperform rating on shares of Merck & Co., Inc. (NYSE:MRK), citing ongoing concerns about the pharmaceutical giant's Gardasil vaccine as a key factor ...

On Friday, Leerink Partners maintained an Outperform rating on shares of Merck & Co., Inc. (NYSE:MRK), citing ongoing concerns about the pharmaceutical giant's Gardasil vaccine as a key factor ...